Drug Trial Radar · NCT02265510
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Last checked: Nov 19, 2026Latest source record: Apr 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
83
Actual
Start
Sep 10, 2014
Primary completion
Feb 27, 2019
Study completion Feb 27, 2019
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Oct 16, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a study of INCB052793 given to patients with advanced malignancies that was to be conducted in three phases; Phase 1a (Monotherapy) and Phase 1b (Combination Therapy) and Phase 2 (Combination therapy of INCB052793 with azacitidine and itacitinib with azacitidine). Phase 1 had two parts; a dose escalation (Part 1) and an expansion (Part 2).
Conditions
- Solid Tumors
- Advanced Malignancies
- Metastatic Cancer
Interventions
INCB052793Drug
Initial cohort dose of INCB052793 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.
gemcitabineDrug
Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency.
nab-paclitaxelDrug
nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency.
dexamethasoneDrug
Dexamethasone administered orally at the protocol-specified dose and frequency.
CarfilzomibDrug
Carfilzomib administered intravenously at the protocol-specified dose and frequency.
bortezomibDrug
Bortezomib administered intravenously or subcutaneously at the protocol-specified dose and frequency.
lenalidomideDrug
Lenalidomide administered orally at the protocol-specified dose and frequency.
azacitidineDrug
Azacitidine administered subcutaneously at the protocol-specified dose and frequency.
INCB052793Drug
INCB052793 tablets administered orally at the protocol specified dose strength and frequency.
pomalidomideDrug
Pomalidomide administered orally at the protocol-specified dose and frequency.
INCB050465Drug
INCB050465 tablets administered orally at the protocol specified dose strength and frequency.
INCB039110Drug
INCB039110 tablets administered orally at the protocol specified dose strength and frequency.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a and 1b: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)Time frame: From first dose of study drug up to 30 days after last dose of study drug (Up to approximately 3.4 years)
- Phase 2: Objective Response Rate (ORR) in Hematological MalignanciesTime frame: Baseline through end of study (Up to approximately 4.5 years)
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
West Hollywood, California
Site not named
New Haven, Connecticut
Site not named
Atlanta, Georgia
Site not named
Chicago, Illinois
Site not named
Indianapolis, Indiana
Site not named
Hackensack, New Jersey
Site not named
New York, New York
Site not named
Durham, North Carolina
Site not named
Portland, Oregon
Site not named
Greenville, South Carolina
Site 2
Nashville, Tennessee
Site not named
Nashville, Tennessee
Site not named
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.